|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 黏籽西瓜、籽瓜和普通西瓜的植物学性状比较分析显示文摘西瓜属于葫芦科的重要水果作物,栽培类型丰富多样,其中黏籽西瓜、籽瓜和普通西瓜是被人类栽培和食用的主要类型,但是这3种类型西瓜的植物学性状差异并没有被系统调查过。针对18份黏籽西瓜、38份籽瓜、174份普通西瓜品种的14个植物学性状进行调查和统计分析,结果显示,供试西瓜品种的植物学性状变异范围大,不同性状在3种类型西瓜之间的差异显著,籽瓜和黏籽西瓜的表型更相似。系统聚类和PCA分析可以将3种类型的西瓜品种基本区分开来,籽瓜介于黏籽西瓜和普通西瓜之间。该研究结果有助于充分了解和利用西瓜种质资源,能够为培育理想株型和优质的西瓜新品种提供科学依据。 | 袁平丽 龚成胜 何楠 刁卫楠 Muhammad Jawad Umer 朱红菊 杨东东 Muhammad Anees 路绪强 Kaseb M O 赵胜杰 刘文革 | 2021 | 中国瓜菜2021，34，9： | 2 |
| 2 | Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction显示文摘 | Manal M. Hassan Ahmed Kaseb Carol J. Etzel Hashem El‐Serag Margaret R. Spitz Ping Chang Katherine S. Hale Mei Liu Asif Rashid Mohamed Shama James L. Abbruzzese Evelyne M. Loyer Harmeet Kaur Hesham M. Hassabo Jean‐Nicolas Vauthey Curtis J. Wray Basmah S. H | 2013 | Mol Carcinog2013，，1： | 2 |
| 3 | Phase II trial of bevaci- zumab and erlotinib as a second-line therapy for advanced hepato- cellular carcinoma显示文摘 | Kaseb AO Morris JS Iwasaki M | 2016 | Onco Targets Ther2016，9，： | 1 |
| 4 | Modified cisplatin/interferon a-2b/doxombicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellu- lar carcinoma显示文摘 | Kaseb AO Shindoh J Patt YZ | 2013 | Cancer2013，119，18： | 1 |
| 5 | Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer 显示文摘 | Banerjee S Kaseb AO Wang Z | 2009 | CancerRes2009，69，13： | 1 |
| 6 | Management of hep- atocellular carcinoma显示文摘 | Asham EH Kaseb A Ghobrial RM | 2013 | The Surgical clinics of North Amer- ica2013，93，6： | 1 |
| 7 | Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma显示文摘BACKGROUND Recurrent hepatitis C virus(HCV)infection of transplanted liver allografts is universal in patients with detectable HCV viremia at the time of transplantation.Direct-acting antiviral(DAA)therapy has been adopted as the standard of care for recurrent HCV infection in the post-transplant setting.However,there are insufficient data regarding its efficacy in liver transplant(LT)recipients with a history of hepatocellular carcinoma(HCC),and the risk of HCC recurrence after DAA therapy is unknown.predictors of DAA treatment failure and HCC recurrence in LT recipients.METHODS A total of 106 LT recipients given DAAs for recurrent HCV infection from 2015 to 2019 were identified(68 with and 38 without HCC).Descriptive statistics and logistic regression models were used to estimate the multivariate odds ratios and respective 95%confidence intervals for predictors of treatment failure and HCC recurrence.RESULTS Six patients(6%)experienced DAA therapy failure post-LT and 100(94%)had a sustained virologic response at follow-up week 12.A high alanine transaminase level>35 U/L at treatment week 4 was a significant predictor of treatment failure.Relapse to pre-LT DAA therapy is a predictor of post-LT HCC recurrence,P=0.04.DAA relapse post-LT was also associated with post-transplantation HCC recurrence,P=0.05.CONCLUSION DAAs are effective and safe in the treatment of recurrent HCV infection in LT recipients with history of HCC.Relapse to pre-and post-LT DAA therapy is associated with post-transplantation HCC recurrence. | Mohamed Saleh Ismail Manal Hassan Saira Aijaz Khaderi Wael Ahmed Yousry Maha Mohsen Kamal El-Din Mohamed Mohamed Bahaa El-Din Osama Aboelfotoh El Sayed Ahmed Omar Kaseb John Alan Goss FasihaKanwal Prasun Kumar Jalal | 2020 | World Journal of Hepatology2020，12，9： | 1 |
| 8 | Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States显示文摘 | Hassan MM Kaseb A Li D | 2009 | Hcpatology2009，49，： | 1 |
| 9 | Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone inpancreatic cancer 显示文摘 | Banerjee S Kaseb AO Wang Z | 2009 | Cancer Res2009，69，13： | 1 |
| 10 | Clinical and prognostic implications of plasma insulin-like growth factor-1and vascular endothelial growth factor in patients with hepatocellular carcinoma显示文摘 | Kaseb AO Morris JS Hassan MM | 2011 | J Clin Oncol2011，，29： | 1 |
| 11 | Clinical and prognostic im- plications of plasma insulin - like growth factor - 1 and vascular endo- thelial growth factor in patients with hepatocellular carcinoma显示文摘 | Kaseb AO Morris JS Hassan MM | 2011 | J Clin Onco12011，29，29： | 1 |
| 12 | Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction显示文摘 | Hassan MM Kaseb A Etzel C J | 2013 | Mol Carcinog2013，521，： | 1 |
| 13 | Association between hypothy- roidism and hepatocellular carcinoma: a case-control study in the United States显示文摘 | Hassan MM Kaseb A Li D | 2009 | Hepatology2009，49，5： | 1 |
| 14 | Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer显示文摘 | Kaseb AO Chinnakannu K Chen D | 2007 | Cancer Res2007，67，16： | 1 |
| 15 | Antitumor activity of gemcit- abine and oxaliplatin is augmented by thymoquinone in pancreatic cancer显示文摘 | Banerjee S Kaseb AO Wang Z | 2009 | Cancer Res2009，69，13： | 1 |
| 16 | Antitumor activity of gemc- itabine and oxaliplatin is augmented by thymoqainone in pancreatic cancer显示文摘 | Banerjee S Kaseb AO Wang Z et a/ | 2009 | Cancer Res2009，69，13： | 1 |
| 17 | Association betweenhypothyroidism and hepatocellular carcinoma:a case-controlstudy in the United States显示文摘 | Hassan MM Kaseb A Li D | 2009 | Hepatology2009，49，5： | 1 |
| 18 | Vascular endothelial growth factor in the management of hepatocellular carcinoma:a review of literature显示文摘 | Kaseb AO Hanbali A Cotant M | 2009 | Cancer2009，115，21： | 1 |
| 19 | Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer显示文摘 | Kaseb AO Chinrtakannu K Chen D et a/ | 2007 | Cancer Res2007，67，16： | 1 |
| 20 | Clinical and prognosticimplications of plasma insulin-like growth factor-1 and vascular en-dothelial growth factor in patients with hepatocellular carcinoma显示文摘 | Kaseb A O Morris J S Hassan M M | 2011 | Clin Oncol2011，10，29： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员